Replies to post #364671 on Amarin Corp Plc (AMRN)

[Number sleven]

ggwpq, Your not wrong. PCSK9 inhibitors also aren't cheap. Vascepa is going to gain traction in the CVD market. Like you said, the math is on our side. Not that I think this will happen, but insurance formularies should be changed. Lipid altering drugs should be listed separately from CVD drugs.
Sleven,